BGLC

BioNexus Gene Lab Corp. (BGLC) | Rumor.io

BioNexus Gene Lab

BGLC

Attention (50-day avg)0%

Attention rank (50-day avg)#4,083

Bullish sentiment (50-day avg)100%

Price to earnings ratio-0.81

Market capitalization3.8M

Earnings per share-1.26

Dividend yield (TTM)—

Revenue (annual)7.4M

Net income (annual)-3M

Social

What share of all stock conversation is about BGLC?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jun 10

BioNexus Gene Lab Corp. ($BGLC) saw a price increase to $5 before dropping to $2.50.
Insiders own 85% of the company, which may be a factor in its current price.
The stock is considered oversold and undervalued, with a small float and potential for a reversal.

Generated by AI

Sentiment

Of the messages about BGLC that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	93.44% +8.46
Bearish	—	—	0% 0	6.56% -8.46

Bullish· Sep 12

BioNexus Gene Lab Corp. (BGLC) has shown strength in its price movement, following the lead of another stock, GCTK, which has gained 150% from $4 to double digits.
BGLC has a solid buy zone below $5, with a potential breakout above $5.70 that could propel it to become the next runner like GCTK.
BGLC has a low float and is poised to explode, with a recent $5 million buy order premarket indicating a potential run-up in its price.

Bearish· Jul 30

* The short interest in BGLC has increased by 71% to 13% of the float, with the cost to borrow exceeding 500% average.
* The company is running low on cash, with only $100,000 in the bank, and is expected to go negative soon based on its cash burn.
* There is a significant risk of a crash, with multiple posts warning of a potential huge drop in price, including a possible reversal of the stock's recent gains.

Generated by AI

Topics

Of the messages about BGLC that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	68.75%
Analysts	—	—	—	4.86%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	5.56%
Technical Analysis	—	—	—	20.83%

Announcements· Oct 20

BioNexus Gene Lab Corp. ($BGLC) has entered a partnership with BirchBioMed Inc. to lead its $10 million funding round through an equity investment and collaboration.
The partnership involves BGLC receiving 1.5 million Birch common shares and providing regulatory and commercialization support in Malaysia and Singapore.
The news has driven BGLC stock up 16% premarket, with traders eyeing continuation of the momentum play.

Technical Analysis· Jul 1

BioNexus Gene Lab Corp. ($BGLC) may be a good entry point if it dips to $9.25-$9.50 and shows a green reversal candle with volume.
The stock's price action is influenced by the 50 EMA and 9 EMA, with the 50 EMA providing support at around $10.
$BGLC has potential targets at $12.80, $15.00, and $18.50 if it continues higher, with support at $9.40.

Generated by AI

Community

Of the messages about BGLC, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	100%	67.81%
Newcomers	—	—	0%	32.19%

Regulars· Aug 4

$BGLC broke out past resistance on strong volume, with RSI confirming bullish momentum, sparking excitement about its potential.
The recent partnership between BioNexus Gene Lab Corp. and another company is being hailed as a "DeepSeek-class leap" for liquid biopsy cancer monitoring and AI-driven biotechnology.
This strategic partnership has the potential to drive significant growth in the biotech sector, with regulars closely watching for its impact on $BGLC's stock.

Newcomers· Oct 20

BioNexus Gene Lab Corp has entered a partnership with BirchBioMed to lead its $10M funding round through equity investment and collaboration.
The partnership involves a strategic term sheet and a significant equity investment from BirchBioMed, which could lead to a dominant role in Birch's funding round.
The partnership could reshape the biotech landscape and redefine how we think about gene innovation, with potential implications for the future of bioengineering.

Generated by AI

Meetings in Shanghai and Changzhou link VitaGuard's commercial use in China with BioNexus' Southeast Asian plans and Fidelion's international licensing efforts Dr. Muthu Meyyappan, Chief Commercial Officer of Fidelion Diagnostics, meets with representatives of Tongshu Gene during working sessions in China focused on VitaGuard™ technology transfer, implementation planning and international commercialization. Dr. Muthu Meyyappan, Chief Commercial Officer of Fidelion Diagnostics, meets with represe

2mo agoYahoo Finance

12 Industrials Stocks Moving In Thursday's Pre-Market Session - EOS ENERGY RIGHT (NASDAQ:EOSER), Decent H

Gainers Eos Energy Enterprises, Inc. - Right (NASDAQ:EOSER) stock increased by 74.7% to $0.05 during Thursday's pre-market session. Decent Holding (NASDAQ:DXST) shares rose 22.11% to $2.54. The market value of

2mo agoBenzinga

Also Discussed

Investors talking about BGLC also mention

#	Name	Attention
1	WRNT - Warrantee Inc. American Depositary Shares	——
2	Millennium Group International Holdings LimitedMGIH	0%0
3	ICCT - iCoreConnect Inc.	——
4	Carmell CorporationCTCX	0%0
5	Cheetah Net Supply Chain Service Inc.CTNT	0.02%-0.01
6	U Power Limited Class A Ordinary SharesUCAR	0%0
7	MINM - Minim, Inc.	——
8	AWIN - AERWINS Technologies Inc.	——
9	Earlyworks Co., Ltd. ADRELWS	0%0
10	Psq Holdings Inc.PSQH	0%0

BioNexus Gene Lab Corp.

Basic Materials
Specialty Chemicals

BioNexus Gene Lab Corp. is a biotechnology and specialty chemicals company based in Kuala Lumpur, Malaysia. The company operates through business segments that include industrial chemical trading and genomic screening services. Through its subsidiaries, it supplies chemical raw materials used in industrial, medical, appliance, automotive, mechanical, and electronic manufacturing across Southeast Asia. BioNexus Gene Lab Corp. also develops blood-based diagnostic services that apply functional genomics and RNA analysis to support early disease detection and personalized health management. Its business model combines distribution of specialty materials with laboratory-focused healthcare solutions, positioning the company at the intersection of industrial supply chains and precision diagnostics. This mix gives BioNexus Gene Lab Corp. a role in both regional manufacturing markets and emerging molecular testing services.

Website

Location

Menara UOA Bangsar

Kuala Lumpur, 59000

Malaysia

Social

What share of all stock conversation is about BGLC?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jun 10

BioNexus Gene Lab Corp. ($BGLC) saw a price increase to $5 before dropping to $2.50.
Insiders own 85% of the company, which may be a factor in its current price.
The stock is considered oversold and undervalued, with a small float and potential for a reversal.

Generated by AI

Sentiment

Of the messages about BGLC that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	93.44% +8.46
Bearish	—	—	0% 0	6.56% -8.46

Bullish· Sep 12

BioNexus Gene Lab Corp. (BGLC) has shown strength in its price movement, following the lead of another stock, GCTK, which has gained 150% from $4 to double digits.
BGLC has a solid buy zone below $5, with a potential breakout above $5.70 that could propel it to become the next runner like GCTK.
BGLC has a low float and is poised to explode, with a recent $5 million buy order premarket indicating a potential run-up in its price.

Bearish· Jul 30

* The short interest in BGLC has increased by 71% to 13% of the float, with the cost to borrow exceeding 500% average.
* The company is running low on cash, with only $100,000 in the bank, and is expected to go negative soon based on its cash burn.
* There is a significant risk of a crash, with multiple posts warning of a potential huge drop in price, including a possible reversal of the stock's recent gains.

Generated by AI

Topics

Of the messages about BGLC that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	68.75%
Analysts	—	—	—	4.86%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	5.56%
Technical Analysis	—	—	—	20.83%

Announcements· Oct 20

BioNexus Gene Lab Corp. ($BGLC) has entered a partnership with BirchBioMed Inc. to lead its $10 million funding round through an equity investment and collaboration.
The partnership involves BGLC receiving 1.5 million Birch common shares and providing regulatory and commercialization support in Malaysia and Singapore.
The news has driven BGLC stock up 16% premarket, with traders eyeing continuation of the momentum play.

Technical Analysis· Jul 1

BioNexus Gene Lab Corp. ($BGLC) may be a good entry point if it dips to $9.25-$9.50 and shows a green reversal candle with volume.
The stock's price action is influenced by the 50 EMA and 9 EMA, with the 50 EMA providing support at around $10.
$BGLC has potential targets at $12.80, $15.00, and $18.50 if it continues higher, with support at $9.40.

Generated by AI

Community

Of the messages about BGLC, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	100%	67.81%
Newcomers	—	—	0%	32.19%

Regulars· Aug 4

$BGLC broke out past resistance on strong volume, with RSI confirming bullish momentum, sparking excitement about its potential.
The recent partnership between BioNexus Gene Lab Corp. and another company is being hailed as a "DeepSeek-class leap" for liquid biopsy cancer monitoring and AI-driven biotechnology.
This strategic partnership has the potential to drive significant growth in the biotech sector, with regulars closely watching for its impact on $BGLC's stock.

Newcomers· Oct 20

BioNexus Gene Lab Corp has entered a partnership with BirchBioMed to lead its $10M funding round through equity investment and collaboration.
The partnership involves a strategic term sheet and a significant equity investment from BirchBioMed, which could lead to a dominant role in Birch's funding round.
The partnership could reshape the biotech landscape and redefine how we think about gene innovation, with potential implications for the future of bioengineering.

Generated by AI

BioNexus Gene Lab

Social

Jun 10

Sentiment

Bullish· Sep 12

Bearish· Jul 30

Topics

Announcements· Oct 20

Technical Analysis· Jul 1

Community

Regulars· Aug 4

Newcomers· Oct 20

News

12 Industrials Stocks Moving In Friday's Pre-Market Session

BioNexus Advances VitaGuard™ Southeast Asia Rollout Following China Working Visit

12 Industrials Stocks Moving In Thursday's Pre-Market Session - EOS ENERGY RIGHT (NASDAQ:EOSER), Decent H

Also Discussed

BioNexus Gene Lab Corp.

Company Information

Location

News

12 Industrials Stocks Moving In Friday's Pre-Market Session

BioNexus Advances VitaGuard™ Southeast Asia Rollout Following China Working Visit

12 Industrials Stocks Moving In Thursday's Pre-Market Session - EOS ENERGY RIGHT (NASDAQ:EOSER), Decent H

Also Discussed

Social

Jun 10

Sentiment

Bullish· Sep 12

Bearish· Jul 30

Topics

Announcements· Oct 20

Technical Analysis· Jul 1

Community

Regulars· Aug 4

Newcomers· Oct 20